Abstract: Objective: To understand existing care practices and policies, and potential enhancements, to improve the effectiveness of the US Department of Veterans Affairs (VA) …
Abstract: Background: Gender-affirming hormone therapy (GAHT) is a common medical intervention sought by transgender and gender diverse (TGD) individuals. Initiating GAHT in …
Abstract: Background: Mental health conditions are highly prevalent among US veterans. The Veterans Health Administration (VHA) is committed to enhancing mental health care through …
Abstract: The Department of Veterans Affairs (VA) is the largest provider of integrated health care services in the United States and its mission is to honor veterans by providing …
Abstract: Objective: To explore financial barriers and facilitators to promoting secure firearm and medication storage among patients at risk for suicide. Methods: Veterans seeking …
Abstract: Exposure-based treatments such as prolonged exposure therapy (PE) are effective for veterans with PTSD. However, dropout rates as high as 50% are common. The Department …
Abstract: Background: Employment has been shown to be the fourth most commonly reported need for veterans and their families, and unemployment rates have ranged from 1–69% …
Abstract: Combat-related physical injuries not only affect the individual but also close family members. Emerging evidence indicates that injuries that change appearance, such as …
Abstract: Forces in Mind Trust’s mission is that all ex-Service persons and their families make a successful and sustainable transition to civilian life, a principle closely …
Abstract: Purpose: The Veterans Health Administration (VHA) is the largest integrated healthcare system in the U.S. While preventive healthcare services are high priority in the …
Abstract: Background: The number of cases of all types of dementia is increasing, and a significant increase in prevalence has been noted among veterans. Evidence of an association …
Abstract: Objective: To identify factors associated with non-treatment with biologic and non-biologic disease modifying anti-rheumatic drugs (DMARDs) during the 12 months after …